Cost comparison of F(ab’) <sub>2</sub> and Fab antivenoms for pit viper envenomation in the United States: a real-world analysis

Patients administered Fab had higher post-index total, inpatient, and inpatient pharmacy costs than patients administered F(ab')<sub>2</sub> AV.

Authors

Mitch DeKoven (ORCID: https://orcid.org/0000-0001-9346-6202)
Swapna Munnangi (ORCID: https://orcid.org/0000-0002-6382-482X)
Walter García-Ubbelohde
Lia Pizzicato (ORCID: https://orcid.org/0000-0002-3889-7138)
Liucheng Shi (ORCID: https://orcid.org/0009-0003-8028-0195)
Nicholas B. Hurst (ORCID: https://orcid.org/0000-0001-7298-7105)
Keith Boesen

Institutions

University of Arizona (US)
IQVIA (United Kingdom) (GB)
IQVIA (United States) (US)
Rare Disease Therapeutics (United States) (US)

Publication Details

Journal: Expert Review of Pharmacoeconomics & Outcomes Research
Published: 2025-02-11
DOI: https://doi.org/10.1080/14737167.2025.2462236
Citations: 1
Primary Topic: Venomous Animal Envenomation and Studies
Type: article
Field-Weighted Citation Impact: 1.82

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Cost comparison of F(ab’) ₂ and Fab antivenoms for pit viper envenomation in the United States: a real-world analysis

Mitch DeKoven, Swapna Munnangi, Walter García-Ubbelohde, Lia Pizzicato et al.

Feb 11, 2025

1 citations

Expert Review of Pharmacoeconomics & Outcomes Research

Venomous Animal Envenomation and Studies

1.82

article

Cost comparison of F(ab’) ₂ and Fab antivenoms for pit viper envenomation in the United States: a real-world analysis

Mitch DeKoven, Swapna Munnangi, Walter García-Ubbelohde, Lia Pizzicato, Liucheng Shi, Nicholas B. Hurst, Keith Boesen

February 11, 2025article en

1 citations

Abstract

Patients administered Fab had higher post-index total, inpatient, and inpatient pharmacy costs than patients administered F(ab')<sub>2</sub> AV.

Expert Review of Pharmacoeconomics & Outcomes ResearchVol. 25(5)

University of Arizona (US), IQVIA (United Kingdom) (GB), IQVIA (United States) (US), Rare Disease Therapeutics (United States) (US)

Zero hunger

Openalex Percentile: Top 18%

Venomous Animal Envenomation and Studies

1.82

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Cost comparison of F(ab’) <sub>2</sub> and Fab antivenoms for pit viper envenomation in the United States: a real-world analysis — Mitch DeKoven, Swapna Munnangi, et al. · Expert Review of Pharmacoeconomics & Outcomes Research (2025) | TGRS Research Map | TGRS